Brooks Ensign
CFO & TreasurerMr. Brooks Ensign was Interim Chief Financial Officer of NuvOx Therapeutics, Inc. from February 10, 2025 to July 4, 2025. Mr. Ensign is Chief Financial Officer and Treasurer of Swarmer, Inc from January 2026. Mr. Ensign’s prior experience includes senior finance and accounting roles with software and life sciences companies. From February 2025 until January 2026, Mr. Ensign served as a consultant for various clients, including serving as Interim CFO for Nuvox Therapeutics, Inc. from February 2025 to July 2025. He previously served as Vice President, Controller for Aptose Biosciences Inc., a clinical-stage biotechnology company developing targeted cancer therapies, from December 2022 until September 2024. Previously, Mr. Ensign served as Global Corporate Controller and Acting Chief Financial Officer from July 2021 to October 2022 for Silvaco Group, Inc. (Silvaco), a multinational semiconductor design software company, where he led the global finance and account teams in preparation for Silvaco’s initial public offering. He also served as the controller for Nervana Systems, Inc., a deep learning artificial intelligence start-up that was subsequently acquired by Intel Corporation for 408 million. Earlier in his career, Mr. Ensign managed corporate development transactions in Central and Eastern Europe for ICN Pharmaceuticals, Inc. Mr. Ensign was an officer in the U.S. Navy, with combat experience in the Persian Gulf. Mr. Ensign received his M.B.A. from Harvard Business School, his B.A. from Harvard College and his Master’s degree in Accounting from National University, where he has also served as an instructor in finance and data science since 2013.
Positions
- Company NameSwarmer, IncStock CodeSWMRPositionCFO & TreasurerColleagues
- AFAlexander FinkPresident, CEO of U.S. & Director
- EDErik Dean PrinceIndependent Chairman
- SKSerhii KupriienkoCo-Founder & Director
- OFOleksii FilippenkovVice President of Operations
- JDJennifer DeTraniChief Legal Officer, VP, General Counsel & Secretary
- PWPhilip WagenheimIndependent Director
- AFAmir FrenkelIndependent Director
